menu
    • menu

    Company profile for Daiichi Sankyo

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    dmfs-not-supported-m-2025-05-19

    Virtual Booth

    Contact Supplier

    Chirogate is a professional Prostaglandin manufacturer.

    Virtual Booth

    Contact Supplier

    Temad- We think of world-class quality.

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we crea...
    Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. We provide innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, our company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients. Through the outstanding knowledge and commitment of our 15,000 employees worldwide, we create innovative new and generic medicines, and new methods of drug discovery and delivery. We share a passion for innovation, as well as compassion for the patients around the world who are in need of our medicines.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Daiichi Sankyojapan Flag
    Country
    Country
    Japan
    Address
    Address
    3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo 103-8426
    Telephone
    Telephone
    +81-3-6225-1111
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.daiichisankyo.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/daiichi-sankyo
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/daiichisankyo?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI North America

    Not Confirmed

    envelop Contact Supplier

    CPhI North America

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    micAlchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets

    With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

    Impressions: 274

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

    Radio Compass
    06 May 2025
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    ReelPharmaConnecting People, Mentalities & MarketsConnecting People, Mentalities & Markets

    Connecting People, Mentalities & Markets
    Connecting People, Mentalities & Markets

    reelConnecting People, Mentalities & Markets

    This PharmaReel highlights Transo-Pharm USA’s offerings of premium Phyto Cannabidiol (CBD) and Phyto Cannabigerol (CBG) isolates from its cGMP-certified facility inspected by the FDA and ANVISA. The company has an expanded reach across the US and EU.

    Impressions: 332

    read-more

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    DMF filings surge 44% in Q1 2025; India tops list with 51% rise in year-on-year submissions

    The first quarter (Q1) of 2025 witnessed an impressive surge in Drug Master File (DMF) submissions to the US Food and Drug Administration (FDA), signaling a robust expansion in pharmaceutical development activities, the looming threat of tariffs notwithstanding.A total of 339 Type II DMFs were submitted during this period, as opposed to 235 submissions in Q1 2024, marking an exceptional increase of 44.26 percent. PharmaCompass’ data suggests that this is a record high for any first quarter.Overall, 440 DMFs were submitted across all categories (Types II, III, IV, and V) during Q1 2025, compared to 353 in the same period last year — representing a 24.65 percent increase.India and China continued to dominate the DMF landscape. India led with 162 submissions in Q1 2025, posting a remarkable 51.4 percent increase over 107 submissions recorded in Q1 2024. China followed with 135 submissions, representing a 33.66 percent increase over the 101 filings in Q1 2024.Taiwan sprung a surprise as a distant third. It made 12 DMF submissions in Q1 2025, as opposed to just one in Q1 2024. Western countries like the US, Spain, Germany, and Italy have maintained relatively stable or declining submission rates. Only the Netherlands showed significant growth with four DMF submissions in Q1 2025, up from zero in Q1 2024. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available)Indian giants MSN, Aurobindo, Cipla, Dr Reddy’s lead record-breaking DMF surgeIndia lived up to its “pharmacy of the world” reputation with the highest DMF submissions. In fact, seven of the top eight companies in the DMF tally were headquartered in India. MSN Group, emerged as the unequivocal leader with 23 submissions in Q1 2025, as against 15 in Q1 2024. Aurobindo Pharma increased its DMF activity from seven submissions in Q1 2024 to 12 in Q1 2025. Alivus Life Sciences, formerly known as Glenmark, made a dramatic leap with eight submissions in Q1 2025, quadrupling its previous year’s count of just two. Cipla more than doubled its DMF submissions — from three in Q1 2024 to eight in Q1 2025.Dr. Reddy’s Laboratories, one of India’s largest generic drugmakers, filed seven DMF submissions. The company’s Q1 2025 DMF portfolio includes high-value molecules like deucravacitinib, finerenone, enzalutamide, niraparib tosylate monohydrate, tucatinib, and tizanidine hydrochloride.Dr. Reddy’s has also indicated that they are open to manufacturing in the US. Meanwhile, Hetero Drugs filed seven submissions while Lee Pharma recorded six in Q1 2025.Chinese manufacturer Jiangsu East-Mab Biomedical Technology also established a significant presence with six DMFs. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Semaglutide, finerenone see most DMF submissions; first-time filings surge 64%Semaglutide and finerenone emerged as the most documented molecules in Q1 2025, each garnering nine DMF submissions. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that has revolutionized diabetes management and weight loss treatment, continues to attract significant manufacturer interest. Similarly, finerenone, a non-steroidal drug used in treating chronic kidney disease in type 2 diabetes patients, has garnered attention from manufacturers.Carfilzomib, used in multiple myeloma treatment, secured the third position with five DMF submissions. Deucravacitinib, a novel drug approved for moderate to severe plaque psoriasis, followed with four DMF submissions.There were several molecules with three DMF submissions each. Among them were tapinarof, a novel drug for psoriasis, and tirzepatide, a GLP-1/GIP receptor agonist that has shown remarkable efficacy in diabetes and weight management. During the quarter, 23 molecules received their inaugural DMF submissions. This number has risen by 64 percent since Q1 2024, when only 14 drugs saw their first DMF filings.In Q1 2025, these 23 first-time molecules collectively garnered 30 DMF submissions, with deucravacitinib emerging as the clear leader. Indian companies Dr. Reddy’s Laboratories and Cipla filed DMFs for this plaque psoriasis treatment as did Spain’s Curia and PMC Global.The Q1 2025 roster of first-time DMF filings include retatrutide (another GLP-1 receptor agonist), sotagliflozin, setmelanotide acetate, daridorexant, nusinersen, zavegepant, belzutifan, elacestrant dihydrochloride, selumetinib sulfate, sotorasib, atogepant, omadacycline tosylate, osilodrostat phosphate, ensifentrine, landiolol hydrochloride, maralixibat chloride, maribavir, methyl olivetolate, diazoxide choline, sparsentan, thinnertide, and vismodegib. View FDA DMF Filings in Q1 2025 (Power BI Dashboard, Free Excel Available) Our viewGiven Trump’s rhetoric around tariffs on imported drugs, the record-breaking DMF submissions in Q1 2025 sent out a strong message that the global pharmaceutical industry is willing to take on the complex geopolitical situation with resilience and strategic foresight.On a different note, the rise in DMF filings also indicate increased workload for the FDA staff, as also more inspections by the agency. It seems like more ‘laid off’ FDA employees will be asked to return to work in the coming days.
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 519

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-surge-44-in-q1-2025-india-tops-list-with-51-rise-in-year-on-year-submissions

    #PharmaFlow by PHARMACOMPASS
    15 May 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Begins
    IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Begins

    19 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250519791895/en/IDeate-Esophageal01-Phase-3-Trial-of-Ifinatamab-Deruxtecan-Initiated-in-Certain-Patients-with-Pretreated-Advanced-or-Metastatic-Esophageal-Squamous-Cell-Carcinoma

    BUSINESSWIRE
    19 May 2025
    Share Share
    AZ, Daiichi's Enhertu tops SOC in early-stage breast cancer
    AZ, Daiichi's Enhertu tops SOC in early-stage breast cancer

    08 May 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/astrazeneca-daiichi-sankyos-enhertu-rings-success-another-breast-cancer-trial

    FIERCE PHARMA
    08 May 2025
    Share Share
    Enhertu Boosts Response in High-Risk HER2+ Breast Cancer
    Enhertu Boosts Response in High-Risk HER2+ Breast Cancer

    07 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250507813535/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-followed-by-THP-before-surgery-showed-statistically-significant-and-clinically-meaningful-improvement-in-pathologic-complete-response-in-high-risk-HER2-positive-early-stage-breast-cancer-in-DESTINY-Breast11

    BUSINESSWIRE
    07 May 2025
    Share Share
    Daiichi Sankyo reports solid launch for touted ADC Datroway
    Daiichi Sankyo reports solid launch for touted ADC Datroway

    29 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/daiichi-sankyo-astrazenecas-highly-touted-adc-datroway-smooth-market-launch

    FIERCE PHARMA
    29 Apr 2025
    Share Share
    Enhertu drives strong efficacy in first-line breast cancer
    Enhertu drives strong efficacy in first-line breast cancer

    22 Apr 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250420186313/en/ENHERTU-Plus-Pertuzumab-Demonstrated-Highly-Statistically-Significant-and-Clinically-Meaningful-Improvement-in-Progression-Free-Survival-Versus-THP-as-First-Line-Therapy-for-Patients-with-HER2-Positive-Metastatic-Breast-Cancer

    BUSINESSWIRE
    22 Apr 2025
    Share Share
    Daiichi Sankyo honors its roots at DC cherry blossom fest
    Daiichi Sankyo honors its roots at DC cherry blossom fest

    17 Apr 2025

    // FIERCE PHARMA

    https://www.fiercepharma.com/marketing/daiichi-sankyo-celebrates-its-roots-and-blooming-future-dc-cherry-blossom-festival

    FIERCE PHARMA
    17 Apr 2025
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Daiichi Sankyo and get a quotation

    Daiichi Sankyo is a supplier offers 77 products (APIs, Excipients or Intermediates).

    Find a price of Ofloxacin bulk with CEP offered by Daiichi Sankyo

    Find a price of Olmesartan Medoxomil bulk with CEP offered by Daiichi Sankyo

    Find a price of Pravastatin bulk with CEP offered by Daiichi Sankyo

    Find a price of Codeine bulk with JDMF offered by Daiichi Sankyo

    Find a price of Codeine Phosphate bulk with JDMF offered by Daiichi Sankyo

    Find a price of Deruxtecan bulk with DMF offered by Daiichi Sankyo

    Find a price of Etilevodopa bulk offered by Daiichi Sankyo

    Find a price of Human Ghrelin bulk with DMF offered by Daiichi Sankyo

    Find a price of Hydromorphone Hydrochloride bulk with JDMF offered by Daiichi Sankyo

    Find a price of Oxycodone Hydrochloride bulk with JDMF offered by Daiichi Sankyo

    Find a price of MUCOPOLYSACCHARIDE POLYSULFATE DRUG SUBSTANCE bulk with DMF offered by Daiichi Sankyo

    Find a price of 2-Naphthalenepropanoic Acid bulk offered by Daiichi Sankyo

    Find a price of Benfluorexum bulk offered by Daiichi Sankyo

    Find a price of Carperitide bulk offered by Daiichi Sankyo

    Find a price of Cefmetazole bulk offered by Daiichi Sankyo

    Find a price of Cefmetazole Sodium bulk offered by Daiichi Sankyo

    Find a price of Cefpodoxime Proxetil bulk offered by Daiichi Sankyo

    Find a price of Cetraxate bulk offered by Daiichi Sankyo

    Find a price of Cs 023 bulk offered by Daiichi Sankyo

    Find a price of Edoxaban Tosylate bulk offered by Daiichi Sankyo

    Find a price of Enkephalin, Methionine bulk offered by Daiichi Sankyo

    Find a price of Faropenem Medoxomil bulk offered by Daiichi Sankyo

    Find a price of Hydrochlorothiazide bulk offered by Daiichi Sankyo

    Find a price of L-VALINE bulk offered by Daiichi Sankyo

    Find a price of Levofloxacin bulk offered by Daiichi Sankyo

    Find a price of Levofloxacin Hydrochloride bulk offered by Daiichi Sankyo

    Find a price of MALOTILATE bulk offered by Daiichi Sankyo

    Find a price of Managlinat Dialanetil bulk offered by Daiichi Sankyo

    Find a price of Mepirizole bulk offered by Daiichi Sankyo

    Find a price of Nimustine bulk offered by Daiichi Sankyo

    Find a price of Ofloxacin bulk offered by Daiichi Sankyo

    Find a price of Olmesartan Medoxomil bulk offered by Daiichi Sankyo

    Find a price of Pantethine bulk offered by Daiichi Sankyo

    Find a price of Phenylalanine bulk offered by Daiichi Sankyo

    Find a price of Pravastatin bulk offered by Daiichi Sankyo

    Find a price of Temocapril Hydrochloride bulk offered by Daiichi Sankyo

    Find a price of Tranexamic Acid bulk offered by Daiichi Sankyo

    Find a price of Troglitazone bulk offered by Daiichi Sankyo

    Find a price of Tryptophan bulk offered by Daiichi Sankyo

    Find a price of DZ-697B DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of CS-834 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of DK-507K DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of SUN N 8075 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of BULK CS-045 ORAL HYPOGLYCEMIC bulk offered by Daiichi Sankyo

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN EDOGAWA-KU, TOKYO, JAPAN. bulk offered by Daiichi Sankyo

    Find a price of CS-758 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of CS-505 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of MIX-RR bulk offered by Daiichi Sankyo

    Find a price of DE-310 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of DS-1594B DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of SUN13837 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of CS-780 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of DW-908E DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of CS-834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of PARENTERAL FORMULATION FACILITY IN OSAKA, JAPAN. bulk offered by Daiichi Sankyo

    Find a price of CS-003 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of FACILITIES AND OPERATING PROCEDURES IN HIRATSUKA-SHI, JAPAN bulk offered by Daiichi Sankyo

    Find a price of CS-758 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of DX-8951F DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of DL 8280 MEFOXACIN ACTIVE & PLACEBO TABS bulk offered by Daiichi Sankyo

    Find a price of SUN N4057 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of DS-1594B DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of SUN13834 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of DX-619 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of DS-4152 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of CS-003 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of DT-5621 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of PANTOSIN 200 MG TABLETS bulk offered by Daiichi Sankyo

    Find a price of PRODUCTION TECHNOLOGY RESEARCH LABS., EDOGAWA-KU, TOKYO, JAPAN bulk offered by Daiichi Sankyo

    Find a price of DATICHI PHARMACEUTICAL CO LTD DU-6859A bulk offered by Daiichi Sankyo

    Find a price of CS-505 DRUG SUBSTANCE bulk offered by Daiichi Sankyo

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN SHIZUOKA JAPAN. bulk offered by Daiichi Sankyo

    Find a price of POLYSULFATED GLYCOSAMINOGLYCAN (PSGAG) bulk offered by Daiichi Sankyo

    Find a price of CS-011 DRUG PRODUCT bulk offered by Daiichi Sankyo

    Find a price of Glycosaminoglycan bulk offered by Daiichi Sankyo

    Find a price of Loxoprofen Sodium bulk offered by Daiichi Sankyo

    Find a price of Mirogabalin Besylate bulk offered by Daiichi Sankyo

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search